<DOC>
	<DOCNO>NCT01303419</DOCNO>
	<brief_summary>Enrolled woman undergo bilateral 2-view DE-CEDM examination administration iodinate contrast agent . Separate reader on-site evaluate DE-CEDM+MX ( standard mammography ) CE-BMRI+MX determine extent disease . An integrated reading set image perform either one two reader . DE-CEDM use change diagnosis . Lesions confirm suspicious MX , CE-BMRI , follow-up breast ultrasound ( US ) undergo biopsy . Truth extent disease base histologic analysis surgical specimen along follow-up MX 10-15 month study exam . A randomized , blind image evaluation do 11 15 radiologist reader compare DE-CEDM+MX CE-BMRI+MX assessment disease extent .</brief_summary>
	<brief_title>Contrast-Enhanced Digital Mammography ( CEDM ) Identifying Change Management Women With Newly Diagnosed Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Woman 21 year age older The subject able willing comply study procedure sign date informed consent obtain . Newly diagnose Breast Cancer ( DCIS invasive ) identify core biopsy fineneedle aspiration ( FNA ) within last 30 day . Will bilateral CEBMRI perform within 30 day AFTER new breast cancer diagnosis . Woman already lumpectomy index lesion . Woman undergo neoadjuvant chemotherapy treatment , hormone treatment radiation therapy . Woman pregnant believe may pregnant . Woman breast implant . Woman contraindication intravenous use iodinate gadoliniumchelated contrast agent ( e.g. , allergy either agent severely impaired renal function ) .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>mammography</keyword>
</DOC>